[New information on the DIC/sepsis program, ADCC, and miscellaneous items.]
What is GTC’s business all about? #msg-19391437What is the business model? #msg-15638633 Further musings on the business model #msg-17935613 Venn diagram of business model #msg-19390137 Edited transcript from 1Q07 conference call (5/3/07) #msg-17607391 Edited transcript from 4Q06 conference call (3/5/07) #msg-9243634 Jan 2006 interview with CEO, Geoff Cox #msg-9352093 2002 interview with Tom Newberry (dated, but still informative) #msg-13171505“Production of Recombinant Therapeutic Proteins in the Milk of Transgenic Animals” (recommended for the technical reader) #msg-17598322 Reference info on biogeneric/biosimilar drugs #msg-19999027 Apropos to ADCC (Vectibix)
ATryn DIC/sepsis program #msg-20150779Scientific rationale for ATryn in DIC/sepsis (summary version) #msg-20150658Scientific rationale for ATryn in DIC/sepsis (detailed version) #msg-16968800 How sepsis causes DIC #msg-12483101Existing therapeutic options are weak #msg-12480578Sepsis incidence is on the rise #msg-16968788 Sepsis incidence is on the rise (addendum) #msg-8316050 Leo Pharma partnership announcement #msg-12430822Economics of the Leo partnership #msg-12511434 Phase-3 timeline #msg-14495208 When will GTC receive milestone payments? #msg-15305927 Design issues in the phase-2 trial
Other potential uses of ATryn #msg-19225820 Reference list of abstracts and write-ups #msg-19226464 How much product would be needed?
Risks and availability of plasma-derived proteins #msg-17114738Salient quote from CEO of ZymoGenetics #msg-7306242 Which antithrombin will doctors prescribe? #msg-4372780 Risks of plasma-derived proteins #msg-17684473 Risks of plasma-derived proteins (addendum) #msg-15535360 Risks of plasma-derived proteins (Mad Cow) #msg-16098448 Limited supply of plasma-derived proteins #msg-16098453 Limited supply of plasma-derived proteins (addendum)
GTC-LFB program in Factor VIIa (and other therapies) #msg-13731860Who is LFB? #msg-13956439 Who is LFB? (addendum) #msg-13708619Partnership terms #msg-15247168How the collaboration works #msg-16164190Sky-high FVIIa price (rationale for GTC/LFB program); everything you always wanted to know about FVIIa in practice #msg-16645259 NovoSeven reaches blockbuster status #msg-16968837FVIIa sales projections #msg-13763244Patient pool for initial indication (hemophilia w/inhibitors) #msg-19404190 rFVIIa as a prophylactic treatment #msg-14084250 NovoSeven for acquired hemophilia #msg-13925693 NovoSeven for trauma #msg-14921693 NovoSeven use in the military
Products derived from transgenic animals: #msg-18396260 Roche / Therapeutic Human Polyclonals #msg-16835174 Technical issues with transgenic chickens #msg-19420912 Viragen / Oxford BioMedica (chickens) #msg-16512199 Viragen admits it has a lot of work to do #msg-7542154 Origen (chickens) #msg-15899425 Kirin/Hematech (cows) #msg-18894630 Argentine cows produce insulin